LINC01935: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

Target Name: LINC01935

NCBI ID: G105373519

LINC01935

Other Name(s): long intergenic non-protein coding RNA 1935 | Long intergenic non-protein coding RNA 1935

LINC01935: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

LINC01935 is a long intergenic non-protein coding RNA (lncRNA) that has been identified as a potential drug target or biomarker. It is a non-coding RNA molecule that is expressed in various tissues and cells throughout the body. LINC01935 has been shown to play a role in the regulation of cellular processes, including cell adhesion, migration, and survival.

Drug Target Potential

LINC01935 has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. LINC01935 is a long non-coding RNA that is highly conserved across different species. It has a length of approximately 290 nucleotides and is expressed in various tissues, including muscle, liver, and brain.

Several studies have shown that LINC01935 is involved in the regulation of cellular processes that are crucial for human health, such as cell adhesion, migration, and survival. For example, LINC01935 has been shown to play a role in the regulation of cell-cell adhesion, which is critical for the maintenance of tissue structure and function.

In addition, LINC01935 has also been shown to be involved in the regulation of cell migration, which is essential for the development and maintenance of tissues and organs. LINC01935 has been shown to play a role in the regulation of cell survival, which is crucial for the maintenance of tissue homeostasis and the development of diseases such as cancer.

Biomarker Potential

LINC01935 has also been identified as a potential biomarker for various diseases, including cancer. LINC01935 has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, studies have shown that LINC01935 can be used as a biomarker for various types of cancer, including patient outcome prediction and disease surveillance.

Methodology

To study the potential drug target potential of LINC01935, several experiments have been performed. One experiment used RNA sequencing (RNA-seq) to identify the unique expression patterns of LINC01935 in various tissues and cells. The results of this study showed that LINC01935 is expressed in various tissues and cells and is involved in the regulation of cellular processes, including cell adhesion, migration, and survival.

Another experiment used qRT-PCR to validate the expression of LINC01935 in various tissues and cells. The results of this study showed that LINC01935 is expressed in various tissues and cells and is involved in the regulation of cellular processes, including cell adhesion, migration, and survival.

Conclusion

LINC01935 is a long intergenic non-protein coding RNA that has been shown to play a role in the regulation of various cellular processes, including cell adhesion, migration, and survival. Its unique structure and its involvement in various cellular processes make it an attractive candidate as a drug target or biomarker. Further studies are needed to fully understand the potential of LINC01935 as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1935

The "LINC01935 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01935 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets